Claims

1. The use of pidotimod or its physiologically acceptable salts thereof, in the manufacture of a medicament for the treatment of Ankylosing Spondylitis, Autoimmune cardiomyopathy, Autoimmune connective tissue diseases, Autoimmune enteropathy, Autoimmune hepatitis, Autoimmune peripheral neuropathy, Autoimmune pancreatitis, Autoimmune polyendocrine syndrome, Autoimmune thrombocytopenic purpura, Autoimmune urticaria, Autoimmune uveitis, Celiac disease, Chronic Fatigue Syndrome, Cystic fibrosis, Hashimoto's thyroiditis, Idiopathic pulmonary fibrosis, Idiopathic thrombocytopenic purpura, IgA nephropathy, Juvenile idiopathic arthritis (or Juvenile rheumatoid arthritis, or Still’s disease) Kawasaki's disease, Lichen planus, Lupus erythematosus, Rheumatoid arthritis, Rheumatic fever, Sjögren's syndrome, Spondyloarthropathy, Temporal arteritis (or giant cell arteritis), Ulcerative colitis and Urticarial vasculitis.
2. The use according to claim 1, characterized in that the medicament is to be administered to a human.
3. The use according to claim 1, characterized in that the medicament is to be administered systemically.
4. The use according to claim 3, characterized in that the medicament is to be administered by parenteral (intramuscular or intravenous) route or by enteral (oral or rectal) route.
5. The use according to claim 3, characterized in that the medicament is to be administered by means of a solid or liquid formulation.
6. The use according to claim 5, characterized in that said solid formulation has a w/w concentration in pidotimod or a physiologically acceptable salt thereof from 50% to 90%, more preferably from 65% to 80%, most preferably from 70% to 75%.
7. The use according to claim 5, characterized in that said liquid formulation has a w/w concentration in pidotimod or a physiologically acceptable salt

thereof from 0.5% to 20%, more preferably from 1% to 10%, most preferably from 2% to 8%.

8. The use according to claim 5, characterized in that said solid formulation contains an amount of pidotimod or of a physiologically acceptable salt thereof, from 10 to 1000 mg per single dose, more preferably from 50 to 800 mg per single dose.
9. The use according to claim 1, characterized in that the medicament is to be administered topically.
10. The use according to claim 9, characterized in that the medicament is to be administered by dermal, ocular, auricular, nasal, buccal, intranasal, endotracheal, vaginal, intravesical, or rectal route.
11. The use according to claim 9, characterized in that the medicament is to be administered by means of a solid, semisolid or liquid formulation.
12. The use according to claim 11, characterized in that said solid formulation has a w/w concentration in pidotimod or a physiologically acceptable salt thereof from 50% to 90%, more preferably from 65% to 80%, most preferably from 70% to 75%.
13. The use according to claim 11, characterized in that said semi-solid or liquid formulation has a w/w concentration in pidotimod or a physiologically acceptable salt thereof from 0.1% to 30%, more preferably from 1% to 20%, most preferably from 5% to 15%.
14. The use according to any of the preceding claims, characterized in that the medicament is to be administered in combination or in temporal proximity with at least one additional active principle.